Bridge to Life Presents New ILTS 2026 Data Showing VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) Expands Use of Marginal Donor Livers and Preserves Mitochondrial Function for Real-Time Viability Assessment

Bridge to Life Presents New ILTS 2026 Data Showing VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) Expands Use of Marginal Donor Livers and Preserves Mitochondrial Function for Real-Time Viability Assessment

FOR IMMEDIATE RELEASE Bridge to Life Presents New ILTS 2026 Data Showing VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) Expands Use of Marginal Donor Livers and Preserves Mitochondrial Function for Real-Time Viability Assessment Studies

Continue Reading

Bridge to Life™ Secures FDA De Novo Clearance for VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System, the First Ever U.S. Approval for Cold Machine Perfusion in Liver Transplant Preservation

Bridge to Life™ Secures FDA De Novo Clearance for VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System, the First Ever U.S. Approval for Cold Machine Perfusion in Liver Transplant Preservation

Bridge to Life™ Secures FDA De Novo Clearance for VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System, the First Ever U.S. Approval for Cold Machine Perfusion in Liver Transplant Preservation VitaSmart Commercial Launch Expected

Continue Reading